Berenberg Bank Begins Coverage on BioNTech (NASDAQ:BNTX)

Analysts at Berenberg Bank initiated coverage on shares of BioNTech (NASDAQ:BNTX) in a report released on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $130.00 price target on the stock. Berenberg Bank’s target price points to a potential upside of 27.61% from the company’s previous close.

Several other analysts also recently weighed in on BNTX. UBS Group boosted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. TD Cowen reduced their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. HSBC lifted their target price on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Finally, The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the company from $90.00 to $137.00 in a research report on Friday, November 8th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.79.

BioNTech Stock Performance

NASDAQ:BNTX opened at $101.87 on Tuesday. The firm has a market capitalization of $24.42 billion, a PE ratio of -48.51 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The business’s fifty day moving average price is $113.57 and its 200 day moving average price is $97.36. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.73 EPS. On average, sell-side analysts anticipate that BioNTech will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Several hedge funds have recently made changes to their positions in BNTX. FMR LLC raised its holdings in BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC acquired a new position in BioNTech during the 3rd quarter worth approximately $59,485,000. Candriam S.C.A. raised its stake in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after buying an additional 341,311 shares during the period. Finally, Braidwell LP purchased a new stake in shares of BioNTech in the third quarter valued at approximately $29,425,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.